Immunocore Holdings plc American Depositary Shares

Immunocore announced Phase 1 trial results for IMC-I109V, a T cell receptor bispecific candidate targeting hepatitis B virus, showing promising dose-dependent HBsAg reduction and a generally manageable safety profile.

The article highlights three low-cost stocks with potential significant growth: a gold mining company, a footwear retailer, and a biotechnology firm developing cancer treatments, each with unique market opportunities and analyst perspectives.

Immunocore Plc reported Q2 2025 results with 30% revenue growth to $98.0 million, driven by KIMMTRAK sales. Despite revenue success, the company experienced a net loss and continued investing heavily in research and development across multiple clinical programs.

14 analysts have shared their evaluations of Immunocore Hldgs (NASDAQ:IMCR) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somew...

Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.